2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Variables Associated With Intravenous Rehydration and Hospitalization in Children With Acute Gastroenteritis : A Secondary Analysis of 2 Randomized Clinical Trials

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What clinical features are associated with intravenous rehydration and hospitalization in children with acute gastroenteritis?

          Findings

          In this secondary analysis of 2 randomized clinical trials with 1846 children, independent variables associated with intravenous rehydration included a higher clinical dehydration score, care in the US relative to Canada, greater frequency and duration of vomiting, prior intravenous rehydration, and lack of oral ondansetron. A higher clinical dehydration score, care in the US, greater frequency of vomiting, and lack of oral ondansetron were associated with hospitalization.

          Meaning

          These findings suggest that oral ondansetron may support oral rehydration therapy to reduce intravenous rehydration and the hospitalization of children with gastroenteritis.

          Abstract

          This secondary analysis of 2 randomized clinical trials investigates which variables are associated with intravenous rehydration and hospitalization in children with acute gastroenteritis.

          Abstract

          Importance

          Despite guidelines endorsing oral rehydration therapy, intravenous fluids are commonly administered to children with acute gastroenteritis in high-income countries.

          Objective

          To identify factors associated with intravenous fluid administration and hospitalization in children with acute gastroenteritis.

          Design, Setting, and Participants

          This study is a planned secondary analysis of the Pediatric Emergency Research Canada (PERC) and Pediatric Emergency Care Applied Research Network (PECARN) probiotic trials. Participants include children aged 3 to 48 months with 3 or more watery stools in 24 hours between November 5, 2013, and April 7, 2017, for the PERC study and July 8, 2014, and June 23, 2017, for the PECARN Study. Children were from 16 pediatric emergency departments throughout Canada (6) and the US (10). Data were analyzed from November 2, 2018, to March 16, 2021.

          Exposures

          Sex, age, preceding health care visit, distance between home and hospital, country (US vs Canada), frequency and duration of vomiting and diarrhea, presence of fever, Clinical Dehydration Scale score, oral ondansetron followed by oral rehydration therapy, and infectious agent.

          Main Outcomes and Measures

          Intravenous fluid administration and hospitalization.

          Results

          This secondary analysis of 2 randomized clinical trials included 1846 children (mean [SD] age, 19.1 [11.4] months; 1007 boys [54.6%]), of whom 534 of 1846 (28.9%) received oral ondansetron, 240 of 1846 (13.0%) received intravenous rehydration, and 67 of 1846 (3.6%) were hospitalized. The following were independently associated with intravenous rehydration: higher Clinical Dehydration Scale score (mild to moderate vs none, odds ratio [OR], 8.73; 95% CI, 5.81-13.13; and severe vs none, OR, 34.15; 95% CI, 13.45-86.73); country (US vs Canada, OR, 6.76; 95% CI, 3.15-14.49); prior health care visit with intravenous fluids (OR, 4.55; 95% CI, 1.32-15.72); and frequency of vomiting (per 5 episodes, OR, 1.66; 95% CI, 1.39-1.99). The following were independently associated with hospitalization: higher Clinical Dehydration Scale score (mild to moderate vs none, OR, 11.10; 95% CI, 5.05-24.38; and severe vs none, OR, 23.55; 95% CI, 7.09-78.25) and country (US vs Canada, OR, 3.37; 95% CI, 1.36-8.40). Oral ondansetron was associated with reduced odds of intravenous rehydration (OR, 0.21; 95% CI, 0.13-0.32) and hospitalization (OR, 0.44; 95% CI, 0.21-0.89).

          Conclusions and Relevance

          Intravenous rehydration and hospitalization were associated with clinical evidence of dehydration and lack of an oral ondansetron-supported oral rehydration period. Strategies focusing on oral ondansetron administration followed by oral rehydration therapy in children with dehydration may reduce the reliance on intravenous rehydration and hospitalization.

          Trial Registration

          ClinicalTrials.gov Identifiers: NCT01853124 (PERC) and NCT01773967 (PECARN)

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Foodborne Illness Acquired in the United States—Major Pathogens

          Estimates of the overall number of episodes of foodborne illness are helpful for allocating resources and prioritizing interventions. However, arriving at these estimates is challenging because food may become contaminated by many agents (e.g., a variety of bacteria, viruses, parasites, and chemicals), transmission can occur by nonfood mechanisms (e.g., contact with animals or consumption of contaminated water), the proportion of disease transmitted by food differs by pathogen and by host factors (e.g. age and immunity), and only a small proportion of illnesses are confirmed by laboratory testing and reported to public health agencies. Laboratory-based surveillance provides crucial information for assessing foodborne disease trends. However, because only a small proportion of illnesses are diagnosed and reported, periodic assessments of total episodes of illness are also needed. (Hereafter, episodes of illness are referred to as illnesses.) Several countries have conducted prospective population-based or cross-sectional studies to supplement surveillance and estimate the overall number of foodborne illnesses ( 1 ). In 2007, the World Health Organization launched an initiative to estimate the global burden of foodborne diseases ( 2 ). In 1999, the Centers for Disease Control and Prevention provided comprehensive estimates of foodborne illnesses, hospitalizations, and deaths in the United States caused by known and unknown agents ( 3 ). This effort identified many data gaps and methodologic limitations. Since then, new data and methods have become available. This article is 1 of 2 reporting new estimates of foodborne diseases acquired in the United States (hereafter referred to as domestically acquired). This article provides estimates of major known pathogens; the other provides estimates for agents of acute gastroenteritis not specified in this article ( 4 ). Methods Adequate data for preparing national estimates were available for 31 pathogens. We estimated the number of foodborne illnesses, hospitalizations, and deaths caused by these 31 domestically acquired pathogens by using data shown in Table A1 and Technical Appendix 1. Data were mostly from 2000–2008, and all estimates were based on the US population in 2006 (299 million persons). Estimates were derived from statistical models with many inputs, each with some measure of uncertainty ( 5 ). To reflect this uncertainty, we used probability distributions to describe a range of plausible values for all model inputs. We expressed model outputs as probability distributions summarized by a mean point estimate with 90% credible intervals (CrIs). We used 2 types of modeling approaches for different types of data: 1) models that began with counts of laboratory-confirmed illnesses and were adjusted for undercounts (because of underreporting and underdiagnosis) and thus scaled up to the estimated number of illnesses and 2) models that began with a US population and used incidence data to scale down to the estimated number of illnesses (Table 1). The modeling approaches used and parameters of these probability distributions are detailed in Technical Appendix 2 and Technical Appendix 3; the proportions cited are modal values. Table 1 Modeling approaches used to estimate the total number of illnesses for different types of data, United States* Pathogens for which laboratory-confirmed illnesses were scaled up Pathogens for which US population was scaled down Active surveillance data Passive surveillance data Outbreak surveillance data Campylobacter spp. Brucella spp. Bacillus cereus Astrovirus Cryptosporidium spp. Clostridium botulinum Clostridium perfringens Norovirus Cyclospora cayetanensis Giardia intestinalis ETEC† Rotavirus STEC O157 Hepatitis A virus Staphylococcus aureus Sapovirus STEC non-O157 Mycobacterium bovis Streptococcus spp. group A Toxoplasma gondii Listeria monocytogenes Trichinella spp. Salmonella spp., nontyphoidal‡ Vibrio cholerae, toxigenic S. enterica serotype Typhi Vibrio parahaemolyticus Shigella spp. Vibrio vulnificus Yersinia enterocolitica Vibrio spp., other *ETEC, enterotoxigenic Escherichi coli; STEC, Shiga toxin–producing E. coli.
†Numbers of E. coli other than STEC or ETEC assumed to be same as for ETEC.
‡Includes all serotypes other than Typhi. Illnesses Laboratory-based surveillance data were available for 25 pathogens (Table A1). The following events must occur for an illness to be ascertained and included in laboratory-based surveillance: the ill person must seek medical care, a specimen must be submitted for laboratory testing, the laboratory must test for and identify the causative agent, and the illness must be reported to public health authorities. If a break occurs in any of the first 3 steps of this surveillance chain, the causative agent will not be laboratory confirmed (underdiagnosis). Furthermore, although all laboratory-confirmed illnesses are reported by active surveillance, some will not be reported by passive surveillance (underreporting). Therefore, to estimate the number of illnesses caused by pathogens under public health surveillance, we determined the number of laboratory-confirmed illnesses and adjusted for underdiagnosis and, if necessary, for underreporting by using a series of component multipliers. Laboratory-confirmed illnesses for these 25 pathogens were reported through 5 surveillance programs: the Foodborne Diseases Active Surveillance Network (FoodNet) for Campylobacter spp., Cryptosporidium spp., Cyclospora cayetanensis, Shiga toxin–producing Escherichia coli (STEC) O157, STEC non-O157, Listeria monocytogenes, nontyphoidal Salmonella spp., Salmonella enterica serotype Typhi, Shigella spp., and Yersinia enterocolitica; the National Notifiable Diseases Surveillance System (NNDSS) for Brucella spp., Clostridium botulinum, Trichinella spp., hepatitis A virus, and Giardia intestinalis; the Cholera and Other Vibrio Illness Surveillance (COVIS) system for toxigenic Vibrio cholerae, V. vulnificus, V. parahemolyticus, and other Vibrio spp.; the National Tuberculosis Surveillance System (NTSS) for Mycobacterium bovis; and the Foodborne Disease Outbreak Surveillance System (FDOSS) for Bacillus cereus, Clostridium perfringens, enterotoxigenic E. coli (ETEC), Staphylococcus aureus, and Streptococcus spp. group A (Table A1; Technical Appendix 1). When data were available from >1 surveillance system, we used active surveillance data from FoodNet, except for Vibrio spp., for which we used COVIS because of geographic clustering of Vibrio spp. infections outside FoodNet sites. We used data on outbreak-associated illnesses from FDOSS only for pathogens for which no data were available from other systems. Because FoodNet conducts surveillance at 10 sites ( 6 ), we estimated the number of laboratory-confirmed illnesses in the United States by applying incidence from FoodNet to the estimated US population for 2006 ( 7 ). We constructed a probability distribution based on extrapolation of rates by year (2005–2008) in each FoodNet site (Technical Appendix 3). We used data from 2005–2008 because the FoodNet surveillance area was constant during that period and because FoodNet began collecting information on foreign travel in 2004. We used data from 2000–2007 for NNDSS, COVIS, and FDOSS and annual counts of reported illnesses for our probability distributions. Some evidence of trend was found for illness caused by hepatitis A virus, S. aureus, and Vibrio spp.; therefore, recent years were weighted more heavily (Technical Appendix 2, Technical Appendix 3). NTSS was used to determine the number of reported illnesses caused by M. bovis during 2004–2007. We assumed that all laboratory-confirmed illnesses were reported to FoodNet active surveillance in the relevant catchment areas. Because COVIS and NNDSS conduct passive surveillance, we applied an underreporting multiplier (1.1 for bacteria and 1.3 for parasites) derived by comparing incidence of all nationally notifiable illnesses ascertained through FoodNet with that reported to NNDSS (Technical Appendix 4) For the 5 bacteria for which only outbreak data were available, we estimated the number of laboratory-confirmed illnesses by creating an underreporting multiplier as follows. We determined the proportion of illnesses ascertained through FoodNet that were caused by Campylobacter spp., Cryptosporidium spp., C. cayatanensis, L. monocytogenes, Salmonella spp., Shigella spp., STEC, Vibrio spp., and Y. enterocolitica that were also reported to FDOSS as outbreak associated and applied the inverse of this proportion, 25.5, to those pathogens (Technical Appendix 4). We assumed that all illnesses caused by M. bovis were reported to NTSS. To adjust for underdiagnosis resulting from variations in medical care seeking, specimen submission, laboratory testing, and test sensitivity, we created pathogen-specific multipliers. To adjust for medical care seeking and specimen submission, we pooled data from FoodNet Population Surveys in 2000–2001, 2002–2003 ( 8 ), and 2006–2007 (Centers for Disease Control and Prevention, unpub. data) from which we estimated the proportion of persons who in the past month reported an acute diarrheal illness (>3 loose stools in 24 hours lasting >1 day or resulting in restricted daily activities) and sought medical care and submitted a stool sample for that illness. Because persons with more severe illness are more likely to seek care ( 9 ), we estimated pathogen-specific proportions of persons with laboratory-confirmed infections who had severe illness (e.g., bloody diarrhea) and used medical care seeking and stool sample submission rates for bloody (35% and 36%, respectively) and nonbloody (18% and 19%, respectively) diarrhea as surrogates for severe and mild cases of most illnesses (Technical Appendix 3). However, for infections with L. monocytogenes, M. bovis, and V. vulnificus and severe infections with hepatitis A virus, we assumed high rates of medical care seeking (i.e., we assumed that 100% of persons with M. bovis infection and 90% with L. monocytogenes, V. vulnificus, or severe hepatitis A virus infections sought care) and specimen submission (100% for hepatitis A virus and M. bovis, 80% for others). We accounted for percentage of laboratories that routinely tested for specific pathogens (25%–100%) and test sensitivity (28%–100%) by using data from FoodNet ( 10 , 11 ) and other surveys of clinical diagnostic laboratory practices ( Technical Appendix 3). For the 5 pathogens for which data were from outbreaks only, we used the nontyphoidal Salmonella spp. underdiagnosis multiplier. Alternative approaches were used for infections not routinely reported by any surveillance system (i.e., diarrheagenic E. coli other than STEC and ETEC, T. gondii, astrovirus, rotavirus, sapovirus, and norovirus) (Technical Appendix 1, Technical Appendix 2, Technical Appendix 3). We assumed diarrheagenic E. coli other than STEC and ETEC to be as common as ETEC. Illnesses caused by T. gondii were estimated by using nationally representative serologic data from the 1999–2004 National Health and Nutrition Examination Survey ( 12 ) and an estimate that clinical illness develops in 15% of persons who seroconvert ( 13 ). We assumed that 75% of children experience an episode of clinical rotavirus illness by 5 years of age, consistent with findings from other studies ( 14 ), and used this estimate for astrovirus and sapovirus. We estimated norovirus illnesses by applying mean proportion of all acute gastroenteritis caused by norovirus (11%) according to studies in other industrialized countries ( 15 – 18 ) to estimates of acute gastroenteritis from FoodNet Population Surveys ( Table A1; Technical Appendix 1, Technical Appendix 2, Technical Appendix 3) ( 4 ). Hospitalizations and Deaths For most pathogens, numbers of hospitalizations and deaths were estimated by determining (from surveillance data) the proportion of persons who were hospitalized and the proportion who died and applying these proportions to the estimated number of laboratory-confirmed illnesses (Table A1; Technical Appendix 1, Technical Appendix 3). Rates of hospitalization and death caused by G. intestinalis and T. gondii were based on the 2000–2006 Nationwide Inpatient Sample. Because some persons with illnesses that were not laboratory confirmed would also have been hospitalized and died, we doubled the number of hospitalizations and deaths to adjust for underdiagnosis, similar to the method used by Mead et al. ( 3 ) but applied an uncertainty distribution (Technical Appendix 3). For diarrheagenic E. coli other than STEC and ETEC, total numbers of hospitalizations and deaths were assumed to be the same as those for ETEC. For rotavirus, we used previous estimates ( 14 ). For astrovirus and sapovirus, we assumed that the number was 25% that of rotavirus ( 19 , 20 ). Numbers of norovirus hospitalizations and deaths were determined by multiplying the estimated number of hospitalizations and deaths caused by acute gastroenteritis, estimated by using national data on outpatient visits resulting in hospitalization, hospital discharge surveys, and death certificates (Table A1; Technical Appendix 1, Technical Appendix 2, Technical Appendix 3) ( 4 ), by the same norovirus proportion (11%) used to estimate illnesses ( 15 – 18 ). Domestically Acquired Foodborne Illnesses Data from published studies and surveillance were used to determine, for each pathogen, the proportion of illnesses acquired while the person had been traveling outside the United States (Technical Appendix 1, Technical Appendix 2, Technical Appendix 3). The remaining proportion was considered domestically acquired. We based our estimates of the proportion of domestically acquired foodborne illnesses caused by each pathogen on data from surveillance, risk factor studies, and a literature review (Technical Appendix 1, Technical Appendix 2, Technical Appendix 3). Uncertainty Analysis We used empirical data, when available, to define entire distributions or parameters of distributions (Technical Appendix 3). When data were sparse, we made reasoned judgments based on context, plausibility, and previously published estimates. The parametric distribution used for almost all multipliers was a 4-parameter beta (modified PERT) distribution ( 21 ). The first 3 parameters are low, modal, and high. The fourth parameter is related to the variability of the distribution. We typically fixed this last parameter at 4, which yields the simple PERT distribution ( 21 ). However, when describing the outbreak reporting multiplier, we used a value of 20 (Technical Appendix 44). Uncertainty in the estimates is the cumulative effect of uncertainty of each of the model inputs. We iteratively generated sets of independent pathogen-specific adjustment factors and used these multipliers to estimate illnesses, hospitalizations, and deaths (Figure; Technical Appendix 2). On the basis of 100,000 iterations, we obtained empirical distributions of counts corresponding to Bayesian posterior distributions and used these posterior distributions to generate a point estimate (posterior mean) and upper and lower 5% limits for 90% CrIs. Because incidence of illnesses differed by location and over time, we included these variations in the models, which led to wider CrIs than if we had assumed that inputs represented independent random samples of a fixed US population. We used SAS version 9.2 (SAS Institute, Cary, NC, USA) for these analyses. Results Foodborne Illnesses We estimate that each year in the United States, 31 pathogens caused 37.2 million (90% CrI 28.4–47.6 million) illnesses, of which 36.4 million (90% CrI 27.7–46.7 million) were domestically acquired; of these, 9.4 million (90% CrI 6.6–12.7 million) were foodborne (Table 2; expanded version available , www.cdc.gov/EID/content/17/1/7-T2.htm). We estimate that 5.5 million (59%) foodborne illnesses were caused by viruses, 3.6 million (39%) by bacteria, and 0.2 million (2%) by parasites. The pathogens that caused the most illnesses were norovirus (5.5 million, 58%), nontyphoidal Salmonella spp. (1.0 million, 11%), C. perfringens (1.0 million, 10%), and Campylobacter spp. (0.8 million, 9%). Table 2 Estimated annual number of episodes of domestically acquired foodborne illnesses caused by 31 pathogens, United States* Pathogen Laboratory confirmed Multipliers Travel related, % Foodborne, %† Domestically acquired foodborne, mean (90% credible interval) Under-reporting Under-diagnosis Bacteria Bacillus cereus, foodborne 85‡ 25.5 29.3 <1 100 63,400 (15,719–147,354) Brucella spp. 120§ 1.1 15.2 16 50 839 (533–1,262) Campylobacter spp. 43,696¶ 1.0 30.3 20 80 845,024 (337,031–1,611,083) Clostridium botulinum,
foodborne 25§ 1.1 2.0 <1 100 55 (34–91) Clostridium perfringens,
foodborne 1,295‡ 25.5 29.3 <1 100 965,958 (192,316–2,483,309) STEC O157 3,704¶ 1.0 26.1 4 68 63,153 (17,587–149,631) STEC non-O157 1,579¶ 1.0 106.8 18 82 112,752 (11,467–287,321) ETEC, foodborne 53‡ 25.5 29.3 55 100 17,894 (24–46,212) Diarrheagenic E. coli
other than STEC and ETEC 53 25.5 29.3 <1 30 11,982 (16–30,913) Listeria monocytogenes 808¶ 1.0 2.1 3 99 1,591 (557–3,161) Mycobacterium bovis 195¶ 1.0 1.1 70 95 60 (46–74) Salmonella spp., nontyphoidal 41,930¶ 1.0 29.3 11 94 1,027,561 (644,786–1,679,667) S. enterica serotype Typhi 433¶ 1.0 13.3 67 96 1,821 (87–5,522) Shigella spp. 14,864¶ 1.0 33.3 15 31 131,254 (24,511–374,789) Staphylococcus aureus,
foodborne 323‡ 25.5 29.3 <1 100 241,148 (72,341–529,417) Streptococcus spp. group A,
foodborne 15‡ 25.5 29.3 <1 100 11,217 (15–77,875) Vibrio cholerae, toxigenic 8§ 1.1 33.1 70 100 84 (19–213) V. vulnificus 111§ 1.1 1.7 2 47 96 (60–139) V. parahaemolyticus 287§ 1.1 142.4 10 86 34,664 (18,260–58,027) Vibrio spp., other 220§ 1.1 142.7 11 57 17,564 (10,848–26,475) Yersinia enterocolitica 950¶ 1.0 122.8 7 90 97,656 (30,388–172,734) Subtotal 3,645,773 (2,321,468–5,581,290) Parasites Cryptosporidium spp. 7,594¶ 1.0 98.6 9 8 57,616 (12,060–166,771) Cyclospora cayetanensis 239¶ 1.0 83.1 42 99 11,407 (137–37,673) Giardia intestinalis 20,305§ 1.3 46.3 8 7 76,840 (51,148–109,739) Toxoplasma gondii 1.0 0.0 <1 50 86,686 (64,861–111,912) Trichinella spp. 13§ 1.3 9.8 4 100 156 (42–341) Subtotal 232,705 (161,923–369,893) Viruses Astrovirus NA NA NA 0 <1 15,433 (5,569–26,643) Hepatitis A virus 3,576§ 1.1 9.1 41 7 1,566 (702–3,024) Norovirus NA NA NA <1 26 5,461,731 (3,227,078–8,309,480) Rotavirus NA NA NA 0 <1 15,433 (5,569–26,643) Sapovirus NA NA NA 0 <1 15,433 (5,569–26,643) Subtotal 5,509,597 (3,273,623–8,355,568) Total 9,388,075
(6,641,440–12,745,709) *All estimates based on US population in 2006. Modal or mean value shown unless otherwise stated; see Technical Appendix 3 for the parameters of these distributions. STEC, Shiga toxin–producing Escherichia coli; ETEC, enterotoxigenic E. coli; NA, not applicable. 
†Percentage foodborne among domestically acquired illnesses.
‡Passive surveillance data on outbreak-associated illnesses from the Foodborne Disease Outbreak Surveillance System. Estimates based on the number of foodborne illnesses ascertained in surveillance and therefore assumed to reflect only foodborne transmission.
§Passive surveillance data from Cholera and Other Vibrio Illness Surveillance or the National Notifiable Disease Surveillance System.
¶Active surveillance data from Foodborne Diseases Active Surveillance Network, adjusted for geographic coverage; data from the National Tuberculosis Surveillance System for M. bovis. Hospitalizations We estimate that these 31 pathogens caused 228,744 (90% CrI 188,326–275,601) hospitalizations annually, of which 55,961 (90% CrI 39,534–75,741) were caused by contaminated food eaten in the United States (Table 3). Of these, 64% were caused by bacteria, 27% by viruses, and 9% by parasites. The leading causes of hospitalization were nontyphoidal Salmonella spp. (35%), norovirus (26%), Campylobacter spp. (15%), and T. gondii (8%). Table 3 Estimated annual number of domestically acquired foodborne hospitalizations and deaths caused by 31 pathogens, United States* Pathogen Hospitalization rate, %† Hospitalizations, mean
(90% credible interval) Death
rate, %† Deaths, mean
(90% credible interval) Bacteria Bacillus cereus, foodborne‡ 0.4 20 (0–85) 0 0 Brucella spp. 55.0 55 (33–84) 0.9 1 (0–2) Campylobacter spp. 17.1 8,463 (4,300–15,227) 0.1 76 (0–332) Clostridium botulinum, foodborne‡ 82.6 42 (19–77) 17.3 9 (0–51) Clostridium perfringens, foodborne‡ 0.6 438 (44–2,008) <0.1 26 (0–163) STEC O157 46.2 2,138 (549–4,614) 0.5 20 (0–113) STEC non-O157 12.8 271 (0–971) 0.3 0 (0–0)§ ETEC, foodborne 0.8 12 (0–53) 0 0 Diarrheagenic E. coli other than STEC and ETEC 0.8 8 (0–36) 0 0 Listeria monocytogenes 94.0 1,455 (521–3,018) 15.9 255 (0–733) Mycobacterium bovis 55.0 31 (21–42) 4.7 3 (2–3) Salmonella spp., nontyphoidal 27.2 19,336 (8,545–37,490) 0.5 378 (0–1,011) S. enterica serotype Typhi 75.7 197 (0–583) 0 0 Shigella spp. 20.2 1,456 (287–3,695) 0.1 10 (0–67) Staphylococcus aureus, foodborne‡ 6.4 1,064 (173–2,997) <0.1 6 (0–48) Streptococcus spp. group A, foodborne‡ 0.2 1 (0–6) 0 0 Vibrio cholerae, toxigenic 43.1 2 (0–5) 0 0 V. vulnificus 91.3 93 (53–145) 34.8 36 (19–57) V. parahaemolyticus 22.5 100 (50–169) 0.9 4 (0–17) Vibrio spp., other 37.1 83 (51–124) 3.7 8 (3–19) Yersinia enterocolitica 34.4 533 (0–1,173) 2.0 29 (0–173) Subtotal 35,796 (21,519–53,414) 861 (260–1,761) Parasites Cryptosporidium spp. 25.0 210 (58–518) 0.3 4 (0–19) Cyclospora cayetanensis 6.5 11 (0–109) 0.0 0 Giardia intestinalis 8.8 225 (141–325) 0.1 2 (1–3) To xoplasma gondii 2.6 4,428 (2,634–6,674) 0.2 327 (200–482) Trichinella spp. 24.3 6 (0–17) 0.2 0 (0–0) Subtotal 4,881 (3,060–7,146) 333 (205–488) Viruses Astrovirus 0.4 87 (32–147) <0.1 0 Hepatitis A virus 31.5 99 (42–193) 2.4 7 (3–15) Norovirus 0.03 14,663 (8,097–23,323) <0.1 149 (84–237) Rotavirus 1.7 348 (128–586) <0.1 0 Sapovirus 0.4 87 (32–147) <0.1 0 Subtotal 15,284 (8,719–23,962) 157 (91–245) Total 55,961 (39,534–75,741) 1,351 (712–2,268) *All estimates based on US population in 2006. STEC, Shiga toxin–producing Escherichia coli; ETEC, enterotoxigenic E. coli. 
†Unadjusted hospitalization and death rates are presented here. These rates were doubled to adjust for underdiagnosis before being applied to the number of laboratory-confirmed cases to estimate the total number of hospitalizations and deaths. The hospitalization and death rates for astrovirus, norovirus, rotavirus, and sapovirus presented here are the percentage of total estimated illness and were not subject to further adjustment.
‡Estimates based on the number of foodborne illnesses ascertained in surveillance, therefore assumed to reflect only foodborne transmission.
§We report median values instead of means for the distributions of deaths caused by STEC non-O157 because of extremely skewed data. Deaths We estimate that these 31 pathogens caused 2,612 deaths (90% CrI 1,723–3,819), of which 1,351 (90% CrI 712–2,268) were caused by contaminated food eaten in the United States (Table 3). Of these, 64% were caused by bacteria, 25% by parasites, and 12% by viruses. The leading causes of death were nontyphoidal Salmonella spp. (28%), T. gondii (24%), L. monocytogenes (19%), and norovirus (11%). Discussion We estimate that foods consumed in the United States that were contaminated with 31 known agents of foodborne disease caused 9.4 million illnesses, 55,961 hospitalizations, and 1,351 deaths each year. Norovirus caused the most illnesses; nontyphoidal Salmonella spp., norovirus, Campylobacter spp., and T. gondii caused the most hospitalizations; and nontyphoidal Salmonella spp., T. gondii, L. monocytogenes, and norovirus caused the most deaths. Scarce data precluded estimates for other known infectious and noninfectious agents, such as chemicals. Foodborne diseases are also caused by agents not yet recognized as being transmitted in food and by unknown agents ( 22 ). The numbers of illnesses caused by these unspecified agents are estimated elsewhere ( 4 ). Studies estimating the overall number of foodborne illnesses have been conducted in England and Wales and in Australia ( 23 , 24 ). Similar to our findings, in Australia norovirus was the leading cause of foodborne illness, accounting for 30% of illnesses caused by known pathogens. In England and Wales, norovirus accounted for only 8% of known foodborne illnesses; however, stool sample reexamination using molecular techniques documented higher rates ( 18 ). Nontyphoidal Salmonella spp. and Campylobacter spp. were leading causes of foodborne illnesses in all 3 countries (England and Wales, Australia, and the United States), although nontyphoidal Salmonella spp. accounted for a greater proportion of illness in the United States. Recent serologic data from Europe suggest that Salmonella spp. infections are more common than estimated by our methods; however, many infections may be asymptomatic ( 25 ). Our estimates did not capture mild illnesses associated with some pathogens. For example, mild cases of botulism are often recognized as part of outbreaks, but affected persons seldom seek medical care and are not captured by surveillance except during outbreaks ( 26 , 27 ). Likewise, L. monocytogenes is rarely diagnosed as the cause of gastroenteritis and fever, partly because this organism is not detected by routine stool culture ( 28 ). Early spontaneous abortion or miscarriage associated with listeriosis may also be underdiagnosed. Accurately estimating hospitalizations and deaths caused by foodborne pathogens is particularly challenging. National data on outpatient visits resulting in hospitalization, hospital discharges, and death certificates probably substantially underestimate pathogen-specific cases because for pathogen-specific diagnoses to be recorded, health care providers must order the appropriate diagnostic tests and coding must be accurate. Particularly in vulnerable populations, dehydration or electrolyte imbalance from a gastrointestinal illness may exacerbate a chronic illness, resulting in hospitalization or death well after resolution of the gastrointestinal illness; thus, the gastrointestinal illness may not be coded as a contributing factor. Moreover, if a pathogen is not detected, infections may be coded as noninfectious illnesses ( 29 ). For norovirus, we estimated the number of hospitalizations and deaths by applying the estimated proportion of acute gastroenteritis illnesses caused by norovirus to overall estimates of hospitalizations and deaths from acute gastroenteritis; this choice is supported by studies of hospitalizations for norovirus ( 30 , 31 ). For most other pathogens, we used data from surveillance to estimate pathogen-specific hospitalizations and deaths and doubled the numbers to adjust for underdiagnosis. More precise information about the degree of undercounting of hospitalizations and deaths for each pathogen would improve these estimates. Our methods and data differed from those used for the 1999 estimates ( 3 ). Our estimate of medical care seeking among persons with a diarrheal illness, derived from the 3 most recent FoodNet Population Surveys conducted during 2000–2007, was higher than that estimated from the 1996–1997 FoodNet Population Survey used for the 1999 estimates (35% and 18% among persons reporting bloody and nonbloody diarrhea, respectively, compared with 15% and 12% in the earlier [1999] study) ( 8 ). These data resulted in lower underdiagnosis multipliers, which contributed to lower estimates of number of illnesses. The biggest change from the earlier estimate was the estimated number of norovirus illnesses, which decreased for 2 reasons. First, the number of acute gastrointestinal illnesses estimated from the FoodNet Population Survey and used in the current study was lower than the estimated number of acute gastrointestinal illnesses used in the 1999 assessment. The earlier study used data from 1996–1997; the sample size was one fifth as large as ours and incorporated data from US studies conducted before 1980 ( 32 , 33 ). Both estimates excluded persons reporting concurrent cough or sore throat, but the proportion of persons reporting these signs and symptoms was higher in the FoodNet Population Surveys we used than that in the older US studies (38% vs. 25%), contributing to a lower estimated prevalence of acute gastroenteritis (0.60 vs. 0.79 episodes/person/year) ( 4 , 32 , 33 ). Additionally, the current study excluded persons with vomiting who were ill for <1 day or whose illness did not result in restricted daily activities, whereas the earlier study included all vomiting episodes. These factors contributed to the new estimate of acute gastroenteritis being 24% lower than the earlier estimate, more likely the result of increased accuracy than a true decrease in illnesses ( 4 ). Second, the lower current estimate for norovirus illnesses resulted from a lower proportion of norovirus estimated to be foodborne (decreased from 40% to 26%); this lower proportion is similar to that estimated in recent studies from other countries ( 23 , 24 ). Because of these reasons and use of other data sources and methods, our estimate cannot be compared with the 1999 estimate for the purpose of assessing trends. FoodNet provides the best data on trends over time ( 34 ). Data used in the current study came from a variety of sources and were of variable quality and representativeness. FoodNet sites, from which we used data for 10 pathogens, are not completely representative of the US population, but 1 study indicated that demographic data from FoodNet and from the 2005 US census did not differ much ( 6 ). For 5 pathogens, only data on foodborne outbreak–related cases were available. No routine surveillance data were available for most viruses, forcing us to use a different modeling approach for viruses than for most other pathogens. Given the large number of norovirus illnesses in these estimates, the paucity of supporting data is a major limitation. Moreover, combining different methods is not optimal because methods themselves may affect the estimates. We chose our modeling approach and used the PERT distribution for many inputs because data were sometimes limited and subjective decisions were required. Other investigators could have chosen other distributions, for good reasons, and arrived at different estimates. Our assumptions about the proportion of illnesses transmitted by food profoundly affect our estimates, but data on which to base these estimates were often lacking. We used data from surveillance, risk factor studies, and the current literature to estimate the proportion of pathogen-specific illnesses caused by consumption of contaminated food ( 35 ), but it is not known how representative these data are of total illnesses and whether the foodborne proportion is similar across age groups. For example, the proportion of some illnesses acquired from animals (e.g., STEC O157) may be higher among children than adults ( 36 ), and the proportions that spread person-to-person (e.g., norovirus) may be higher among institutionalized elderly persons ( 37 ). Because a higher proportion of cases are reportedly associated with hospitalization or death in these vulnerable groups, we may have overestimated the total contribution of foodborne transmission for these outcomes. The methods used for this study could be adapted to estimate the proportion of illnesses attributable to other modes of transmission, such as waterborne and direct animal contact. The estimates from this study can be used to help direct policy and interventions; to conduct other analyses (e.g., evaluation of economic cost of these diseases and attribution to various food commodities); and as a platform for developing estimates of effects of disease caused by sequelae of foodborne infections. Supplementary Material Appendix Overview of Methods and Summary of Data Sources. Appendix Model Structures Used to Make Estimates. Appendix Estimation and Uncertainty Model Inputs for 31 Major Known Pathogens Transmitted Through Food. Appendix Data Used to Estimate Passive and Outbreak Surveillance Underreporting Multipliers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global burden of childhood pneumonia and diarrhoea

            Summary Diarrhoea and pneumonia are the leading infectious causes of childhood morbidity and mortality. We comprehensively reviewed the epidemiology of childhood diarrhoea and pneumonia in 2010–11 to inform the planning of integrated control programmes for both illnesses. We estimated that, in 2010, there were 1·731 billion episodes of diarrhoea (36 million of which progressed to severe episodes) and 120 million episodes of pneumonia (14 million of which progressed to severe episodes) in children younger than 5 years. We estimated that, in 2011, 700 000 episodes of diarrhoea and 1·3 million of pneumonia led to death. A high proportion of deaths occurs in the first 2 years of life in both diseases—72% for diarrhoea and 81% for pneumonia. The epidemiology of childhood diarrhoea and that of pneumonia overlap, which might be partly because of shared risk factors, such as undernutrition, suboptimum breastfeeding, and zinc deficiency. Rotavirus is the most common cause of vaccine-preventable severe diarrhoea (associated with 28% of cases), and Streptococcus pneumoniae (18·3%) of vaccine-preventable severe pneumonia. Morbidity and mortality from childhood pneumonia and diarrhoea are falling, but action is needed globally and at country level to accelerate the reduction.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014.

              These guidelines update and extend evidence-based indications for the management of children with acute gastroenteritis in Europe. The guideline development group formulated questions, identified data, and formulated recommendations. The latter were graded with the Muir Gray system and, in parallel, with the Grading of Recommendations, Assessment, Development and Evaluations system. Gastroenteritis severity is linked to etiology, and rotavirus is the most severe infectious agent and is frequently associated with dehydration. Dehydration reflects severity and should be monitored by established score systems. Investigations are generally not needed. Oral rehydration with hypoosmolar solution is the major treatment and should start as soon as possible. Breast-feeding should not be interrupted. Regular feeding should continue with no dietary changes including milk. Data suggest that in the hospital setting, in non-breast-fed infants and young children, lactose-free feeds can be considered in the management of gastroenteritis. Active therapy may reduce the duration and severity of diarrhea. Effective interventions include administration of specific probiotics such as Lactobacillus GG or Saccharomyces boulardii, diosmectite or racecadotril. Anti-infectious drugs should be given in exceptional cases. Ondansetron is effective against vomiting, but its routine use requires safety clearance given the warning about severe cardiac effects. Hospitalization should generally be reserved for children requiring enteral/parenteral rehydration; most cases may be managed in an outpatients setting. Enteral rehydration is superior to intravenous rehydration. Ultrarapid schemes of intravenous rehydration are not superior to standard schemes and may be associated with higher readmission rates. Acute gastroenteritis is best managed using a few simple, well-defined medical interventions.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                19 April 2021
                April 2021
                19 April 2021
                : 4
                : 4
                : e216433
                Affiliations
                [1 ]Department of Pediatrics, Schulich School of Medicine and Dentistry, London, Canada
                [2 ]Department of Internal Medicine, Schulich School of Medicine and Dentistry, London, Canada
                [3 ]Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, London, Canada
                [4 ]Children's Health Research Institute, London Health Sciences Centre, London, Canada
                [5 ]Division of Emergency Medicine, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
                [6 ]Division of Emergency Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
                [7 ]Department of Pediatrics, University of Utah, Salt Lake City
                [8 ]Department of Emergency Medicine, Columbia University College of Physicians & Surgeons, New York, New York
                [9 ]Department of Pediatrics, University of Utah, Salt Lake City
                [10 ]Division of Gastroenterology, Hepatology, & Nutrition, Department of Pediatrics, Washington University in St Louis School of Medicine, St Louis, Missouri
                [11 ]Division of Emergency Medicine, Department of Pediatrics, Children’s Hospital of Michigan, Detroit
                [12 ]Wayne State University, Detroit, Michigan
                [13 ]Department of Emergency Medicine, University of Michigan, Ann Arbor
                [14 ]Division of Pediatric Emergency Medicine, The Hospital for Sick Children, SickKids Research Institute, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
                [15 ]Department of Emergency Medicine, IWK Health Centre, Halifax, Nova Scotia, Canada
                [16 ]Department of Pediatric Emergency Medicine, Université de Montréal, Montréal, Quebec, Canada
                [17 ]Department of Pediatrics, Université de Montréal, Montréal, Quebec, Canada
                [18 ]Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento
                [19 ]Department of Emergency Medicine, University of California, Davis, School of Medicine, Sacramento
                [20 ]Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
                [21 ]Department of Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada
                [22 ]Pediatric Emergency Department, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
                [23 ]Department of Emergency Medicine, University of New Mexico, Albuquerque
                [24 ]Division of Emergency Medicine, Children's National Hospital, Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC
                [25 ]Department of Emergency Medicine, Rhode Island Hospital/Hasbro Children's Hospital and Brown University, Providence
                [26 ]Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
                [27 ]Sections of Pediatric Emergency Medicine and Gastroenterology, Department of Pediatric Medicine, Alberta Children’s Hospital, Alberta, Canada
                [28 ]Section of Pediatric Emergency Medicine, Department of Emergency Medicine, Alberta Children’s Hospital, Alberta, Canada
                [29 ]Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
                Author notes
                Article Information
                Accepted for Publication: February 26, 2021.
                Published: April 19, 2021. doi:10.1001/jamanetworkopen.2021.6433
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Poonai N et al. JAMA Network Open.
                Corresponding Author: Naveen Poonai, MSc, MD, Schulich School of Medicine & Dentistry, 800 Commissioners Rd E, London, Ontario, N6A 2V5, Canada ( naveen.poonai@ 123456lhsc.on.ca ).
                Author Contributions: Dr Poonai had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Poonai, Schnadower, Tarr, O'Connell, Freedman.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Poonai, Tarr, Mahajan, Freedman.
                Critical revision of the manuscript for important intellectual content: Poonai, Powell, Schnadower, Casper, Roskind, Olsen, Tarr, Rogers, Schuh, Hurley, Gouin, Vance, Farion, Sapien, O'Connell, Levine, Bhatt, Freedman.
                Statistical analysis: Casper, Olsen.
                Obtained funding: Schnadower, Tarr, Freedman.
                Administrative, technical, or material support: Schnadower, Casper, Olsen, Freedman.
                Supervision: Poonai, Freedman.
                Conflict of Interest Disclosures: Dr Freedman reported receiving nonfinancial support from Lallemand Health Solutions, the Provincial Laboratory for Public Health, Luminex Corporation, and Copan Italia, and receiving grants from the Canadian Institutes for Health Research and Alberta Children’s Hospital Foundation. Dr Freedman reported providing consulting services to RedHill Biopharma LTD and Takeda Pharmaceutical Company during the conduct of the study. Dr Powell reported receiving grants from the National Institute of Child Health and Human Development (NICHD) via subcontract and grants from the National Institutes of Health (NIH) via subcontract outside the submitted work. Dr Schnadower reported receiving research grants from NIH/NICHD and nonfinancial support from iHealth Inc during the conduct of the study. Dr Casper reported receiving grants from the NICHD and from the Health Resources and Services Administration (HRSA) during the conduct of the study. Dr Roskind reported receiving grants from the NICHD during the conduct of the study. Dr Olsen reported receiving grants from the NICHD during the conduct of the study. Dr Tarr reported receiving grants from Washington University and the NIH during the conduct of the study. Dr Mahajan reported receiving grants from the NICHD during the conduct of the study. Dr Vance reported receiving grants from the NICHD and the NIH during the conduct of the study. Dr Sapien reported receiving grants from the NIH during the conduct of the study and from the HRSA outside the submitted work. Dr O'Connell reported receiving grants from the NIH during the conduct of the study. Dr Bhatt reported receiving grants from the NIH during the conduct of the study.
                Funding/Support: This work was supported in part by grants 286384 and 325412 from the Canadian Institutes of Health Research (Dr Freedman), the Alberta Children’s Hospital Foundation’s Professorship in Child Health and Wellness (Dr Freedman), a grant from the Alberta Children’s Hospital Foundation to the Pediatric Emergency Medicine Research Associates’ Program, Calgary Laboratory Services (in kind), Provincial Laboratory for Public Health–Alberta Public Laboratories, Luminex Corporation, and Copan Italia. This study was supported in part by grant R01HD071915 from the NICHD (Dr Schnadower) and the Richard and Barbara Ruddy Endowed Chair in Emergency Medicine at Cincinnati Children's Hospital Medical Center (Dr Schnadower). The Pediatric Emergency Care Applied Research Network (PECARN) was supported by the HRSA of the US Department of Health and Human Services (HHS) and the Emergency Medical Services for Children program through the following grants: DCC-University of Utah (U03MC00008), GLEMSCRN-Nationwide Children’s Hospital (U03MC00003), HOMERUN-Cincinnati Children’s Hospital Medical Center (U03MC22684), PEMNEWS-Columbia University Medical Center (U03MC00007), PRIME-University of California at Davis Medical Center (U03MC00001), SW NODE-University of Arizona Health Sciences Center (U03MC28845), WBCARN-Children’s National Medical Center (U03MC00006), and CHaMP-Medical College of Wisconsin (H3MC26201).
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
                Disclaimer: Dr Powell is an Assistant Editor at JAMA Network Open. She was not involved in the editorial review of or decision to publish this article.
                Meeting Presentations: This study was presented as a poster at the Canadian Paediatric Society; June 7, 2019, Toronto, Ontario; as an oral presentation at the Canadian Association of Emergency Physicians; May 29, 2019, Halifax, Nova Scotia; and as a poster presentation at the Pediatric Academic Societies, April 27, 2019; Baltimore, Maryland.
                Data Sharing Statement: See Supplement 4.
                Additional Information: All PERC and PECARN members who fulfilled authorship criteria are listed as coauthors.
                Article
                zoi210211
                10.1001/jamanetworkopen.2021.6433
                8056281
                33871616
                a3bc5aca-b0c9-48fb-9077-9fa1a433e6b6
                Copyright 2021 Poonai N et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 6 October 2020
                : 26 February 2021
                Categories
                Research
                Original Investigation
                Online Only
                Pediatrics

                Comments

                Comment on this article